NAMS
Closed
Newamsterdam Pharma Company N.v. Ordinary Shares
18.22
+0.11 (+0.61%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 18.11
Day's Range: 17.97 - 18.7595
Send
sign up or login to leave a comment!
When Written:
13.56
NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company that focuses on developing novel therapies for patients suffering from rare diseases. The company is headquartered in Amsterdam, Netherlands. Its lead product candidate is NAM-003, a potential treatment for a rare genetic disorder called X-linked hypophosphatemia (XLH). XLH is a disease that affects bone growth and can lead to bone deformities, pain, and weakness. NAM-003 is a recombinant human alkaline phosphatase (recAP) that has been shown to improve bone mineralization and reduce pain in XLH patients in a Phase 2 clinical trial. NewAmsterdam Pharma Company N.V. went public on the Nasdaq Global Market in May 2021, under the ticker symbol NAPA.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








